Clinical Trials
5 trialsNCT03173950 2025-06-29
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00045734 2017-05-15
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00904735 2013-08-12
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 2 Unknown